JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations

Clinical trial NCT06391944 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT06391944
Sponsor: Shanghai JMT-Bio Inc.
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Local Advanced or Metastatic NSCLC Harboring EGFR Common Mutation

Start date: 2021-11-21
Primary completion: 2023-05-17
Enrollment: 161

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.